Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23634923 | 1.00 | CRBN (0.43) | CRBNDDB1CYP1A1CYP2D6CYP2B6 | |
| SCHEMBL23634817 | 1.00 | CRBN (0.43) | CRBNDDB1CYP1A1CYP2D6CYP2B6 | |
| SCHEMBL23634978 | 0.86 | CRBN (0.42) | CRBNDDB1CYP1A1CYP2D6CYP2B6 | |
| SCHEMBL23634974 | 0.86 | CRBN (0.42) | CRBNDDB1CYP1A1CYP2D6CYP2B6 | |
| SCHEMBL23634884 | 0.86 | CRBN (0.42) | CRBNDDB1CYP1A1CYP2D6CYP2B6 | |
| SCHEMBL23635084 | 0.86 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL23634999 | 0.86 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL23634971 | 0.86 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL23634963 | 0.81 | CRBN (0.37) | CRBNDDB1 | |
| SCHEMBL23634849 | 0.81 | CRBN (0.37) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | CRBN, CLNS1A, ADRM1 | CRBN 1/4885DDB1 456/4885CYP1A1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.